Article

Suburethral sling offers resistance to traction

Mentor's Ob-Tape is a suburethral sling used for the trans-obturatortechnique. The sling is made from 100% non-woven polypropylene fibers, whichoffer resistance to traction, tissue colonization, and facilitates positioningduring surgery, according to the company.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
1 expert is featured in this series.
1 expert is featured in this series.
Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
Related Content
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
July 9th 2025

Leva System adds Mayo Clinic overactive bladder content

Benjamin P. Saylor Hannah Clarke
Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
July 8th 2025

UK’s MHRA approves nogapendekin alfa inbakicept plus BCG in NMIBC

Benjamin P. Saylor Hannah Clarke
According to the company, the MHRA approval represents the first marketing approval outside the US for NAI.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
Zelenectide pevedotin plus pembrolizumab shows promising anti-tumor activity in mUC
July 8th 2025

Zelenectide pevedotin plus pembrolizumab shows promising anti-tumor activity in mUC

Hannah Clarke
The data, collected as part of the phase 1/2 Duravelo-1 trial, showed an objective response rate of 65%.
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
July 7th 2025

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Benjamin P. Saylor
For the trial, a biomarker will be utilized to aid in patient selection for the treatment.
© 2025 MJH Life Sciences

All rights reserved.